This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

SciClone Pharmaceuticals (Holdings) Past Earnings Performance

Past criteria checks 6/6

SciClone Pharmaceuticals (Holdings) has been growing earnings at an average annual rate of 10.1%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 15.7% per year. SciClone Pharmaceuticals (Holdings)'s return on equity is 33.9%, and it has net margins of 33.1%.

Key information

10.1%

Earnings growth rate

4.4%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	15.7%
Return on equity	33.9%
Net Margin	33.1%
Last Earnings Update	30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How SciClone Pharmaceuticals (Holdings) makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:SCCP.F Revenue, expenses and earnings (CNY Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 23	2,878	953	808	147
31 Mar 23	2,814	904	781	135
31 Dec 22	2,750	855	753	124
30 Sep 22	2,706	844	738	134
30 Jun 22	2,662	833	724	145
31 Mar 22	2,590	878	726	140
31 Dec 21	2,518	923	729	134
30 Sep 21	2,259	837	742	114
30 Jun 21	2,089	779	753	85
31 Mar 21	2,004	766	703	80
31 Dec 20	1,919	754	653	75
30 Sep 20	2,001	817	615	77
31 Dec 19	1,708	615	579	88
31 Dec 18	1,409	535	533	77
31 Dec 17	1,213	20	728	83
30 Jun 17	1,166	294	586	96
31 Mar 17	1,146	258	587	111
31 Dec 16	1,112	213	591	105
30 Sep 16	1,060	246	544	88
30 Jun 16	1,072	257	550	72
31 Mar 16	1,034	183	515	82
31 Dec 15	1,021	191	509	80
30 Sep 15	991	130	488	129
30 Jun 15	913	102	458	124
31 Mar 15	879	186	442	88
31 Dec 14	836	156	426	90
30 Sep 14	774	133	429	29
30 Jun 14	790	140	467	28
31 Mar 14	770	68	499	57
31 Dec 13	769	66	510	49
30 Sep 13	780	78	541	35
30 Jun 13	816	-56	530	37
31 Mar 13	901	26	535	13
31 Dec 12	974	60	548	32
30 Sep 12	1,024	121	505	56

Quality Earnings: SCCP.F has high quality earnings.

Growing Profit Margin: SCCP.F's current net profit margins (33.1%) are higher than last year (31.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SCCP.F's earnings have grown by 10.1% per year over the past 5 years.

Accelerating Growth: SCCP.F's earnings growth over the past year (14.5%) exceeds its 5-year average (10.1% per year).

Earnings vs Industry: SCCP.F earnings growth over the past year (14.5%) exceeded the Pharmaceuticals industry -17.3%.

Return on Equity

High ROE: SCCP.F's Return on Equity (33.9%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/09/04 12:53
End of Day Share Price	2023/06/07 00:00
Earnings	2023/06/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SciClone Pharmaceuticals (Holdings) Limited is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	B. Riley Wealth
Hamed Khorsand	BWS Financial Inc.
Hangci Zheng	China International Capital Corporation Limited